| Popis: |
The international scientific conference, the EUFEPS/CPhS Conference in Zagreb 'Networking in Pharmaceutical Sciences' was organized by the European Federation for Pharmaceutical Sciences (EUFEPS) and the Croatian Pharmaceutical Society (CPhS) - Section for Pharmaceutical Sciences, under the auspices of the Ministry of Science, Education and Sports of the Republic of Croatia and the Ministry of Health and Social Welfare of the Republic of Croatia, at the GlaxoSmithKline Research centre Zagreb Ltd. (Prilaz baruna Filipovića 29, Zagreb, Croatia). Partners in this organization were the Croatian Agency for Medicinal Products and Medical Devices (ALMP) and the Croatian Association of Research– Based Pharmaceutical Companies (CARPC). The objective of this EUFEPS/CPhS Conference in Zagreb was to strengthen and broaden the international network advancing and supporting pharmaceutical sciences and scientists - through and together with the European Federation for Pharmaceutical Sciences (EUFEPS) - thereby establishing better contacts with national sister societies/institutions/agencies, all pursuing excellence in research, development, education and training. This helps achieve mutual understanding and future collaboration among researchers in all relevant scientific domains and disciplines. At the time when there are strong influences in pharmaceutical sciences, and in mutual tracing of future directions in drug discovery, development and use, there is a need to further encourage and boost biomedical research across Europe. In doing so, the Organizers of this conference believe that there is substantial value in joint actions of stakeholders representing the scientific environment of the industry, regulatory bodies and academia. This conference has been established to share relevant visions, missions and strategies in this field. Scientists who are dealing with drug modelling and simulation, medicinal chemistry, pharmacogenetics/genomics, system approaches, gene therapy, pharmacology, pharmacokinetics, drug metabolism, toxicology, pharmaceutical formulation, drug delivery, pharmaceutical physico-chemistry, new in-vitro/in-vivo models, safety sciences, regulation, and so forth, as well as decision-makers at all levels, have contributed to this event. Since these scientists are involved in pharmaceutical R&D, therefore they support biomedical research for the benefit of patients, it is imperative for all them to accelerate the development of safe and effective medicines for patients. |
